Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

82.75 -0.55 (-0.66%)

Streaming Delayed Price Updated: 1:45 PM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

August 01, 2024

Via ACCESSWIRE

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

July 31, 2024

Via ACCESSWIRE

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗

July 28, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Via Benzinga

AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday ↗

July 24, 2024

Via Benzinga

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 07, 2024

Via ACCESSWIRE

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

March 26, 2024

Via ACCESSWIRE

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

March 06, 2024

Via ACCESSWIRE

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

July 22, 2024

Via ACCESSWIRE

3 Growth Stocks No One Is Watching (But They Should Be) ↗

July 11, 2024

While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential.

Via InvestorPlace

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗

June 28, 2024

Protagonist Therapeutics will join the SmallCap 600 on Wednesday.

Via Investor's Business Daily

Topics Stocks

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

June 13, 2024

Via ACCESSWIRE

The 3 Best Biotech Stocks to Buy in June 2024 ↗

June 05, 2024

Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.

Via InvestorPlace

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

May 31, 2024

Via ACCESSWIRE

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 27, 2024

Via ACCESSWIRE

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

May 14, 2024

Via ACCESSWIRE

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

May 07, 2024

Via ACCESSWIRE

Turnstone Biologics Appoints William Waddill to its Board of Directors

April 16, 2024

From Turnstone Biologics Corp.

Via GlobeNewswire

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

March 18, 2024

Via ACCESSWIRE

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

March 11, 2024

Via ACCESSWIRE

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

February 21, 2024

Via ACCESSWIRE

Protagonist Therapeutics Reports Granting of Inducement Awards

February 20, 2024

Via ACCESSWIRE

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

February 07, 2024

Via ACCESSWIRE

Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? ↗

February 01, 2024

Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 31, 2024

Via Benzinga

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

January 31, 2024

Via ACCESSWIRE

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

January 29, 2024

Via ACCESSWIRE

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

Via ACCESSWIRE

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

December 13, 2023

Via ACCESSWIRE

Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

December 12, 2023

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Contact Us

Contact Us

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

All News about Protagonist Therapeutics, Inc. - Common Stock